Memorial Sloan-Kettering’s Dr. Howard Scher Reaffirms Commitment to Lead Phase I Trials for AV Therapeutics’ Prostate Cancer Drug

[GlobeNewswire] – NEW YORK — AV Therapeutics, Inc. (AV Therapeutics or the Company) (OTCQB:AVTH), a developer of cancer therapeutics and vaccines, announced Howard Scher, MD, Chief, Genitourinary … more

View todays social media effects on MDVN

View the latest stocks trending across Twitter. Click to view dashboard

See who Medivation is hiring next, click here to view